FI4152004T3 - Jc-viruksen vasta-aineiden määritys - Google Patents
Jc-viruksen vasta-aineiden määritys Download PDFInfo
- Publication number
- FI4152004T3 FI4152004T3 FIEP22191259.5T FI22191259T FI4152004T3 FI 4152004 T3 FI4152004 T3 FI 4152004T3 FI 22191259 T FI22191259 T FI 22191259T FI 4152004 T3 FI4152004 T3 FI 4152004T3
- Authority
- FI
- Finland
- Prior art keywords
- jcv
- subject
- hpvlps
- antibody
- sample
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000701460 JC polyomavirus Species 0.000 claims 29
- 238000000034 method Methods 0.000 claims 21
- 239000012472 biological sample Substances 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 13
- 239000002955 immunomodulating agent Substances 0.000 claims 8
- 229940121354 immunomodulator Drugs 0.000 claims 8
- 230000002584 immunomodulator Effects 0.000 claims 8
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000009175 antibody therapy Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000013101 initial test Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000002805 secondary assay Methods 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 238000002810 primary assay Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29404810P | 2010-01-11 | 2010-01-11 | |
| US31619310P | 2010-03-22 | 2010-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4152004T3 true FI4152004T3 (fi) | 2025-02-21 |
Family
ID=44305841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22191259.5T FI4152004T3 (fi) | 2010-01-11 | 2011-01-11 | Jc-viruksen vasta-aineiden määritys |
| FIEP17203178.3T FI3339865T5 (fi) | 2010-01-11 | 2011-01-11 | Jc-viruksen vasta-aineiden määritys |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17203178.3T FI3339865T5 (fi) | 2010-01-11 | 2011-01-11 | Jc-viruksen vasta-aineiden määritys |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9316641B2 (en, 2012) |
| EP (4) | EP2524060B1 (en, 2012) |
| JP (2) | JP5946218B2 (en, 2012) |
| KR (1) | KR101877576B1 (en, 2012) |
| CN (1) | CN102906278A (en, 2012) |
| AU (1) | AU2011203815B2 (en, 2012) |
| BR (1) | BR112012017014B1 (en, 2012) |
| CA (1) | CA2784137A1 (en, 2012) |
| CY (2) | CY1119972T1 (en, 2012) |
| DK (3) | DK2524060T3 (en, 2012) |
| ES (3) | ES2930469T3 (en, 2012) |
| FI (2) | FI4152004T3 (en, 2012) |
| HR (3) | HRP20180356T1 (en, 2012) |
| HU (3) | HUE060312T2 (en, 2012) |
| IN (1) | IN2012DN06139A (en, 2012) |
| LT (3) | LT4152004T (en, 2012) |
| ME (1) | ME03026B (en, 2012) |
| MX (1) | MX341991B (en, 2012) |
| NO (1) | NO2524060T3 (en, 2012) |
| NZ (1) | NZ600681A (en, 2012) |
| PL (3) | PL3339865T3 (en, 2012) |
| PT (3) | PT2524060T (en, 2012) |
| RS (3) | RS56977B1 (en, 2012) |
| SG (2) | SG181653A1 (en, 2012) |
| SI (3) | SI4152004T1 (en, 2012) |
| SM (3) | SMT202200445T1 (en, 2012) |
| WO (1) | WO2011085369A1 (en, 2012) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
| WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| BRPI0708392A2 (pt) | 2006-03-03 | 2011-05-24 | Elan Pharm Inc | métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune |
| AU2010303156B2 (en) | 2009-10-11 | 2016-02-04 | Biogen Ma Inc. | Anti-VLA-4 related assays |
| DK2524060T3 (en) | 2010-01-11 | 2018-03-12 | Biogen Ma Inc | ASSAY FOR JC VIRUS ANTIBODIES |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| HUE043339T2 (hu) * | 2011-05-31 | 2019-08-28 | Biogen Ma Inc | Módszer a PML kockázatának megállapítására |
| EP2791162A2 (en) * | 2011-12-12 | 2014-10-22 | Janssen Diagnostics BVBA | Polyomavirus peptide sequences |
| EP2839032A4 (en) * | 2012-04-16 | 2015-11-18 | Univ Texas | PROOF OF EXCELLULAR JCV MIRNA |
| WO2013192100A1 (en) | 2012-06-18 | 2013-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for detecting jc virus |
| WO2014102399A1 (en) * | 2012-12-31 | 2014-07-03 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| US9949671B2 (en) | 2013-03-13 | 2018-04-24 | Orthoaccel Technologies, Inc. | Diagnostic mouthpieces |
| WO2014193804A1 (en) | 2013-05-28 | 2014-12-04 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| ES2818823T3 (es) | 2014-02-27 | 2021-04-14 | Biogen Ma Inc | Método de evaluación del riesgo de LMP |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| IT201600083859A1 (it) * | 2016-08-09 | 2018-02-09 | Univ Degli Studi Di Ferrara | Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici. |
| US20210002372A1 (en) * | 2018-03-02 | 2021-01-07 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4235601A (en) | 1979-01-12 | 1980-11-25 | Thyroid Diagnostics, Inc. | Test device and method for its use |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US5763262A (en) | 1986-09-18 | 1998-06-09 | Quidel Corporation | Immunodiagnostic device |
| ES2150428T3 (es) | 1987-04-27 | 2000-12-01 | Unilever Nv | Ensayos de union especifica. |
| US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US4818677A (en) | 1987-12-03 | 1989-04-04 | Monoclonal Antibodies, Inc. | Membrane assay using focused sample application |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US5221616A (en) | 1988-07-15 | 1993-06-22 | Quidel Corporation | Prevention of spontaneous complement activation in mammalian biological fluids |
| US5118630A (en) | 1988-11-04 | 1992-06-02 | Quidel Corporation | Method for determining periodic infertility in females |
| US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5084828A (en) | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
| US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
| US5096837A (en) | 1990-02-08 | 1992-03-17 | Pacific Biotech, Inc. | Immunochromatographic assay and method of using same |
| US5223220A (en) | 1990-03-27 | 1993-06-29 | Pacific Biotech, Inc. | Solid phase immunoassay device and method of making same |
| US5118428A (en) | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
| DE4139840B4 (de) | 1990-12-04 | 2005-06-02 | Quidel Corp., San Diego | Antigen-Zubereitung zum Nachweis von H. pylori |
| WO1992012428A1 (en) | 1991-01-11 | 1992-07-23 | Quidel Corporation | A one-step lateral flow nonbibulous assay |
| US5213796A (en) | 1991-05-06 | 1993-05-25 | Dana Farber Cancer Institute | Assay for polyomavirus in humans and uses thereof |
| US5225328A (en) | 1991-05-30 | 1993-07-06 | Quidel Corporation | Stable alkaline phosphatase compositions with color enhancement and their use in assays |
| US5686315A (en) | 1991-06-14 | 1997-11-11 | Quidel Corporation | Assay device for one step detection of analyte |
| JPH07503543A (ja) | 1992-02-04 | 1995-04-13 | クイデル コーポレイション | 乾燥試薬を用いる細菌抗原の簡易化抽出法 |
| US5541069A (en) | 1992-02-28 | 1996-07-30 | Quidel Corporation | Assay having improved dose response curve |
| EP0630475B1 (en) | 1992-03-10 | 2000-09-06 | Quidel Corporation | Red blood cell separation means for specific binding assays |
| EP0678122B1 (en) | 1993-01-12 | 1999-07-28 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| US5415994A (en) | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5434057A (en) | 1994-02-02 | 1995-07-18 | Quidel Corporation | Sperm motility assay and devices |
| US5521102A (en) | 1994-08-08 | 1996-05-28 | Quidel Corporation | Controlled sensitivity immunochromatographic assay |
| US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
| US5804452A (en) | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
| US5786220A (en) | 1995-04-28 | 1998-07-28 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
| US6319676B1 (en) | 1995-05-02 | 2001-11-20 | Carter Wallace, Inc. | Diagnostic detection device and method |
| US5773234A (en) | 1995-08-07 | 1998-06-30 | Quidel Corporation | Method and device for chlamydia detection |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| US6305377B1 (en) | 1996-12-12 | 2001-10-23 | Michael T. Portwood | System and method for improving compliance of a medical regimen |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6306642B1 (en) | 1997-11-24 | 2001-10-23 | Quidel Corporation | Enzyme substrate delivery and product registration in one step enzyme immunoassays |
| US6623981B2 (en) | 1998-01-27 | 2003-09-23 | Bristol-Myers Squibb Company | Detection of patients at risk for developing integrin antagonist/agonist mediated disease states |
| US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US7171371B2 (en) | 1999-09-03 | 2007-01-30 | Smg Trust | Method and system for providing pre and post operative support and care |
| ATE236398T1 (de) | 1999-10-12 | 2003-04-15 | Connex Ges Zur Optimierung Von | Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| ATE447969T1 (de) | 1999-12-16 | 2009-11-15 | Biogen Idec Inc | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin |
| AU4465001A (en) | 2000-03-30 | 2001-10-15 | Nippon Kayaku Kabushiki Kaisha | Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor |
| US6620626B1 (en) | 2000-08-09 | 2003-09-16 | Mission Research Corp. | Antigen detection device and method |
| MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
| AU1038402A (en) | 2000-10-17 | 2002-04-29 | Besst Test Aps | Assay for directly detecting a rs virus related biological cell in a body fluid sample |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| US6485460B2 (en) | 2001-01-12 | 2002-11-26 | Bracco Diagnostics, Inc. | Tamper evident syringe barrel |
| WO2003016902A1 (en) | 2001-08-20 | 2003-02-27 | Proteome Systems Intellectual Property Pty Ltd | Diagnostic testing process and apparatus |
| AU2002331408B2 (en) * | 2001-08-20 | 2008-05-08 | Proteome Systems Ltd | Diagnostic testing process and apparatus |
| US6605602B1 (en) | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| SI1485127T1 (sl) | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| US8478604B2 (en) | 2002-06-21 | 2013-07-02 | Mckesson Technologies Inc. | Closed loop medication use system and method |
| WO2005052567A1 (en) | 2003-11-24 | 2005-06-09 | Biogen Idec Ma Inc. | Methods for detecting half-antibodies using chip-based gel electrophoresis |
| JP4672263B2 (ja) | 2004-01-27 | 2011-04-20 | デンカ生研株式会社 | 簡便な検出法、検出装置及び検出キットとその製法 |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| US20050283385A1 (en) | 2004-06-21 | 2005-12-22 | The Permanente Medical Group, Inc. | Individualized healthcare management system |
| KR101273614B1 (ko) | 2004-07-08 | 2013-06-12 | 엘란 파마슈티칼스, 인크. | 중합체 부분을 포함하는 다가 ｖｌａ―４ 길항제 |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CA2589379A1 (en) | 2004-12-03 | 2006-06-08 | Biogen Idec Ma Inc. | Delaying or preventing onset of multiple sclerosis |
| ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
| CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
| BRPI0616687A2 (pt) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4 |
| US7579466B2 (en) | 2006-02-27 | 2009-08-25 | Elan Pharmaceuticals, Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| EP2007392A4 (en) * | 2006-02-28 | 2010-04-07 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS |
| WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| BRPI0708392A2 (pt) | 2006-03-03 | 2011-05-24 | Elan Pharm Inc | métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune |
| EP1873201B1 (en) * | 2006-06-30 | 2010-09-29 | Sumitomo Rubber Industries, Ltd. | Rubber composition for cap tread and pneumatic tire having cap tread using same |
| EP2089515A4 (en) | 2006-11-16 | 2011-02-23 | Novavax Inc | VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS |
| EP1933140B1 (en) | 2006-12-11 | 2011-08-17 | AraGen Biotechnology Co. Ltd. | Antibody detection method involving an oligonucleotide enhanced collodial gold signal |
| BRPI1016273A2 (pt) | 2009-02-05 | 2020-12-01 | Biogen Idec Ma Inc. | método para a detecção de polimavírus jc |
| CN102326080B (zh) | 2009-02-20 | 2015-08-05 | 加利福尼亚大学董事会 | A+生物标志物的试验 |
| DK2524060T3 (en) | 2010-01-11 | 2018-03-12 | Biogen Ma Inc | ASSAY FOR JC VIRUS ANTIBODIES |
| HUE043339T2 (hu) | 2011-05-31 | 2019-08-28 | Biogen Ma Inc | Módszer a PML kockázatának megállapítására |
-
2011
- 2011-01-11 DK DK11732315.4T patent/DK2524060T3/en active
- 2011-01-11 HU HUE17203178A patent/HUE060312T2/hu unknown
- 2011-01-11 SM SM20220445T patent/SMT202200445T1/it unknown
- 2011-01-11 HU HUE22191259A patent/HUE070903T2/hu unknown
- 2011-01-11 CA CA2784137A patent/CA2784137A1/en active Pending
- 2011-01-11 MX MX2012007660A patent/MX341991B/es active IP Right Grant
- 2011-01-11 WO PCT/US2011/020832 patent/WO2011085369A1/en active Application Filing
- 2011-01-11 IN IN6139DEN2012 patent/IN2012DN06139A/en unknown
- 2011-01-11 EP EP11732315.4A patent/EP2524060B1/en not_active Revoked
- 2011-01-11 ES ES17203178T patent/ES2930469T3/es active Active
- 2011-01-11 HU HUE11732315A patent/HUE036183T2/hu unknown
- 2011-01-11 SM SM20250065T patent/SMT202500065T1/it unknown
- 2011-01-11 HR HRP20180356TT patent/HRP20180356T1/hr unknown
- 2011-01-11 NZ NZ600681A patent/NZ600681A/en unknown
- 2011-01-11 JP JP2012548227A patent/JP5946218B2/ja active Active
- 2011-01-11 SI SI201132127T patent/SI4152004T1/sl unknown
- 2011-01-11 HR HRP20250210TT patent/HRP20250210T1/hr unknown
- 2011-01-11 PT PT117323154T patent/PT2524060T/pt unknown
- 2011-01-11 SG SG2012043154A patent/SG181653A1/en unknown
- 2011-01-11 KR KR1020127019171A patent/KR101877576B1/ko active Active
- 2011-01-11 EP EP24213770.1A patent/EP4524571A3/en active Pending
- 2011-01-11 PL PL17203178.3T patent/PL3339865T3/pl unknown
- 2011-01-11 RS RS20180245A patent/RS56977B1/sr unknown
- 2011-01-11 PL PL22191259.5T patent/PL4152004T3/pl unknown
- 2011-01-11 SI SI201131438T patent/SI2524060T1/en unknown
- 2011-01-11 PT PT172031783T patent/PT3339865T/pt unknown
- 2011-01-11 ES ES22191259T patent/ES3012733T3/es active Active
- 2011-01-11 LT LTEP22191259.5T patent/LT4152004T/lt unknown
- 2011-01-11 DK DK17203178.3T patent/DK3339865T5/da active
- 2011-01-11 SG SG10201500079YA patent/SG10201500079YA/en unknown
- 2011-01-11 AU AU2011203815A patent/AU2011203815B2/en active Active
- 2011-01-11 LT LTEP17203178.3T patent/LT3339865T/lt unknown
- 2011-01-11 SI SI201132069T patent/SI3339865T1/sl unknown
- 2011-01-11 SM SM20180148T patent/SMT201800148T1/it unknown
- 2011-01-11 FI FIEP22191259.5T patent/FI4152004T3/fi active
- 2011-01-11 US US13/521,311 patent/US9316641B2/en active Active
- 2011-01-11 RS RS20250151A patent/RS66509B1/sr unknown
- 2011-01-11 RS RS20221053A patent/RS63744B1/sr unknown
- 2011-01-11 PL PL11732315T patent/PL2524060T3/pl unknown
- 2011-01-11 BR BR112012017014-7A patent/BR112012017014B1/pt active IP Right Grant
- 2011-01-11 ES ES11732315.4T patent/ES2664173T3/es active Active
- 2011-01-11 DK DK22191259.5T patent/DK4152004T3/da active
- 2011-01-11 NO NO11732315A patent/NO2524060T3/no unknown
- 2011-01-11 EP EP17203178.3A patent/EP3339865B9/en active Active
- 2011-01-11 HR HRP20221390TT patent/HRP20221390T1/hr unknown
- 2011-01-11 ME MEP-2018-60A patent/ME03026B/me unknown
- 2011-01-11 FI FIEP17203178.3T patent/FI3339865T5/fi active
- 2011-01-11 CN CN2011800133864A patent/CN102906278A/zh active Pending
- 2011-01-11 LT LTEP11732315.4T patent/LT2524060T/lt unknown
- 2011-01-11 PT PT221912595T patent/PT4152004T/pt unknown
- 2011-01-11 EP EP22191259.5A patent/EP4152004B9/en active Active
-
2015
- 2015-12-18 JP JP2015246985A patent/JP2016040557A/ja not_active Withdrawn
-
2016
- 2016-03-08 US US15/063,777 patent/US10444234B2/en active Active
-
2018
- 2018-02-28 CY CY20181100251T patent/CY1119972T1/el unknown
-
2022
- 2022-11-18 CY CY20221100739T patent/CY1126069T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4152004T3 (fi) | Jc-viruksen vasta-aineiden määritys | |
| US20210190797A1 (en) | Methods and reagents for diagnosis of SARS-CoV-2 infection | |
| JP2013516633A5 (en, 2012) | ||
| Bendall et al. | Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response | |
| JP2014518377A5 (en, 2012) | ||
| MX2009013411A (es) | Deteccion de antigenos transportados por eritrocitos y de anticuerpos anti-eritrocitos. | |
| WO2008026741A1 (fr) | Procédé de diagnostic rapide spécifique du virus de la grippe aviaire | |
| JP2010502187A5 (en, 2012) | ||
| HRP20190860T1 (hr) | POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a | |
| US10408841B2 (en) | Mutated HEV polypeptides and the use thereof for assaying anti-HEV antibodies | |
| RU2018103933A (ru) | Моноклональные антитела, с ориентировкой на антиген Р респираторно-синцитиального вируса человека, получаемые и секретируемые из клеточных гибридом, используемые для обнаружения и диагностики инфекции, вызываемой респираторно-синцитиальным вирусом | |
| Pohanka et al. | Diagnosis of tularemia using piezoelectric biosensor technology | |
| Seaman et al. | Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis | |
| JP2010530960A5 (en, 2012) | ||
| Jagtap et al. | Evaluation of spike protein antigens for SARS-CoV-2 serology | |
| FI3509624T3 (fi) | Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi | |
| Cassaniti et al. | Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area | |
| JP2013506837A5 (en, 2012) | ||
| Mravinacova et al. | A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies | |
| WO2011118982A3 (ko) | 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법 | |
| Wu et al. | Detection of Dengue Fever Nonstructural Protein 1 Antigen by Proteolytic Peptide Imprinting Technology and UHPLC–MS/MS | |
| RU2014114532A (ru) | Способ измерения антитела против wt1 | |
| ES2375095T3 (es) | Utilización del péptido sintético derivado de la proteína zebra para el diagnóstico in vivo de la reactivación del virus de epstein-barr (ebv). | |
| Felbinger et al. | Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals | |
| MY151190A (en) | Method of detecting pork in processed food and detection kit therefor |